# Keunchil Park

Source: https://onco.cc/people/keunchil-park/  
OnCo record `keunchil-park` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Korean lung cancer specialist who led CHRYSALIS, the first human study of amivantamab, whose exon 20 insertion cohort earned the drug its first approval.

## Summary

Keunchil Park is a thoracic medical oncologist at Samsung Medical Center in Seoul. He was first author of the 2021 Journal of Clinical Oncology report of the CHRYSALIS study, which showed that the EGFR-MET bispecific antibody amivantamab produced durable responses in EGFR exon 20 insertion non-small-cell lung cancer after platinum chemotherapy, the basis of the drug's first approval. He has led many EGFR-directed lung cancer trials in Asia.

## Fields

- Kind: Person
- Last checked: 2026-09-18
- Tags: lung; targeted-therapy; trialist
- Role: Medical oncologist and trial lead, Samsung Medical Center, Seoul
- Specialisms: EGFR-mutant lung cancer; Bispecific antibodies; Early-phase trials

## Connected records

- cancers: [EGFR-mutated non-small-cell lung cancer](https://onco.cc/cancers/egfr-mutant-nsclc/), [Lung cancer (all types)](https://onco.cc/cancers/lung-cancer/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- institutions: [Samsung Medical Center](https://onco.cc/institutions/samsung-medical-center/)
- trials: [CHRYSALIS](https://onco.cc/trials/chrysalis/)

---
JSON: https://onco.cc/api/v1/entities/keunchil-park.json